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Abstract
Background: Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease
(COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in
multiple large well-characterized cohorts of susceptible current and former smokers.
Methods: We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from
COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor
necrosis factor (TNF)-α, interferon (IFN)-γ, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated
chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers
were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and
FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype
associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs).
Results: Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3–5% of the measurement
variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6
and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated
with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with
CCL17 plasma measurements.
Conclusion: When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and
eotaxin may add additional modest predictive value on top of clinical variables alone.
Trial registration: COPDGene (ClinicalTrials.gov Identifier: NCT02445183).
Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) (ClinicalTrials.gov Identifier:
NCT 01969344).
Background
Chronic obstructive pulmonary disease (COPD) is typic-
ally caused by decades of exposure to smoke, dust or other
inhaled toxins. The lung is the primary portal of exposure
and bears most of the disease burden. Smoking related
lung injury includes airflow obstruction, emphysema,
chronic bronchitis, and lung cancer; however, there is also
substantial evidence that tobacco smoke causes systemic
disease. For instance, tobacco smoking is a major risk fac-
tor for cardiovascular disease as well as extrapulmonary
malignancies such as bladder, stomach and pancreas [1].
Despite more than 50 years of knowledge that smoking
causes both lung and systemic disease, the molecular basis
for this is not fully understood. Furthermore, most
smokers do not develop clinical lung disease such as
COPD, emphysema, and chronic bronchitis and there is
marked heterogeneity in disease manifestations in those
who do. Since more than 100 million people in the United
States and nearly 1 billion people worldwide are current
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or former smokers, there is a great need to identify diag-
nostic and prognostic biomarkers to assess disease risk
and severity as well as to identify potential novel thera-
peutic targets.
Two strategies exist for developing biomarkers of
COPD. First, one can obtain lung biosamples such as ex-
haled breath, sputum, bronchoalveolar lavage fluid
(BALF), and lung brushes and biopsies. Exhaled breath
is non-invasive, but has poor reproducibility and low
protein content. Sputum requires expertise and time.
BALF and lung brushes and biopsies may provide a
more direct readout of the lung compartment; however,
these sampling techniques are invasive, expensive, and
have more than minimal risk. An alternative strategy for
identifying COPD biomarkers is systemic biosampling,
most commonly by obtaining plasma or serum and less
commonly urine. The primary advantage of this strategy
is ease in obtaining samples, low risk, and high reprodu-
cibility. The disadvantage is that blood may have a
smaller biomarker signal compared to a sample obtained
directly from the lung.
There are several blood biomarkers of varying value in
predicting COPD affection status (case versus control),
severity, and disease progression [2–5]. For instance, fi-
brinogen and C reactive protein (CRP), both non-
specific markers of inflammation, tend to correlate with
COPD severity and risk of exacerbations [6–21], al-
though data are conflicting [22]. A protein which is
abundantly expressed in the lung epithelium, the soluble
receptor for advanced glycation end-products (sRAGE),
is inversely correlated with emphysema and airflow ob-
struction [23–26]. Lung specific proteins such as surfac-
tant protein D (SP-D) and club cell-16 (CC16) are also
attractive COPD biomarkers. SP-D has been associated
with COPD [14, 27–29], and emphysema [25] and pos-
sibly exacerbation frequency [16, 29]. CC16 may correl-
ate with airflow obstruction [30] and emphysema [25].
The major limitation to many of the previous publica-
tions include: small sample size, limited clinical pheno-
typing, and lack of reproducibility in an independent
cohort. In this study, we address some of these limita-
tions by studying 9 blood chemokines and cytokines in
more than 3000 subjects from two well phenotyped lon-
gitudinal cohorts of smokers: COPDGene and
SPIROMICS.
Methods
Study populations
This study includes two independent NIH-funded cohorts:
COPDGene (ClinicalTrials.gov Identifier: NCT02445183)
and Subpopulations and Intermediate Outcomes Mea-
sures in COPD Study (SPIROMICS) (ClinicalTrials.gov
Identifier: NCT 01969344). The institutional review board
at all participating sites approved the study protocols
(Additional file 1: Table S1). Study participants provided
written informed consent.
COPDGene is a multicenter prospective observational
study funded by the NIH which enrolled 10,300 subjects
45–80 years old, with at least a 10 pack-year history of
smoking, and who had not had an exacerbation of
COPD for at least the previous 30 days. The cohort also
includes 108 subjects who never smoked (< 100 lifetime
cigarettes). Subjects were recruited from 2008 to 2011
and were invited to return for a 5-year follow up visit
from 2013 to 2017. Blood was drawn into a vacutainer
EDTA plasma tube, immediately spun, aliquoted, and
frozen. The subset for this current analysis includes the
first 2122 who returned and provided a blood sample
during their 5-year follow up visit. Biomarker measure-
ments were made using plasma from the 5-year follow
up visit. Additional information on the COPDGene
study and the collection of clinical, radiographic, and
spirometry data has been described previously [31].
SPIROMICS is an ongoing multicenter prospective ob-
servational study funded by the NIH [17] that enrolled
2982 subjects between November 2011 and January
2015. Subjects were 40–80 years old at the time of en-
rollment. Subjects were categorized as non-tobacco
smokers (< 1 pack-year; stratum 1) or smokers (> 20
pack-years; Stratum 2–4). At the baseline visit blood was
drawn into a vacutainer EDTA plasma tube, immediately
spun, aliquoted, and frozen. The subset for this current
analysis was 1026 subjects with baseline blood samples
including all subjects with history of smoking but no air-
flow obstruction (N = 551) and a random sample of
those with COPD (N = 566). Additional information on
the SPIROMICS study and the collection of clinical,
radiographic, and spirometry data has been described
previously [32].
Clinical phenotype definitions
COPD was defined by post-bronchodilator forced ex-
piratory volume in the first second (FEV1) to forced vital
capacity (FVC) ratio of < 0.70. Smoker controls were
current or former smokers without evidence of airflow
obstruction (FEV1/FVC ≥ 0.70). Emphysema was defined
by the percent of voxels with Hounsfield Units (HU) <
−950 (%LAA) on inspiratory CT. Emphysema progres-
sion was defined as change in lung density adjusted for
predicted total lung capacity (adj. g/L), but only available
in the COPDGene cohort. Chronic bronchitis (CB) was
defined as the subject reporting chronic cough and spu-
tum production for at least 3 months per year for two
consecutive years [33]. Moderate exacerbations were de-
fined as those treated with steroids and/or antibiotics;
severe exacerbations were defined as those resulting in
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hospitalization. For cross sectional analysis, subjects
where further subcategorized as emphysema (LAA > 5%)
or no emphysema (LAA ≤ 5%).
Biomarker selection and measurement
In a previous COPDGene and SPIROMCIS study we
used a 13-panel luminex-RBM assays to measure 114
candidate plasma and serum biomarkers [34]. Twenty-
six of the biomarkers had more than 50% of the values
below lower limit of detection (LLOD) and were not an-
alyzed. From this list, we selected plasma biomarkers for
further study on a different a Meso Scale Discovery
(MSD, Rockville, Maryland) platform. Biomarker selec-
tion was based on these criteria: (1) inflammation che-
mokine or cytokine with plausible association with
COPD-related phenotypes; (2) below lower limit of de-
tection from a previous study using a luminex-RBM
pane in COPDGene and SPIROMCIS subjects [34]; (3)
had the majority of measurements within the limit of de-
tection in a pilot project (N = 40) using a MSD V-PLEX
Human Cytokine 30-Plex Kit. The 9 cytokines and che-
mokines that met these criteria and were run using two
separate multiplex assays: assay 1 (cytokines)- interleu-
kin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor
(TNF)-α, interferon (IFN)-γ assay 2 (chemokines)-
eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and
activation-regulated chemokine (TARC)/CCL-17. To de-
termine assay coefficients of variation (CVs), first 200
cytokine assays and the first 240 chemokine assays were
performed in duplicate. Assay characteristics of the
MSD assays are shown in Additional file 1: Table S1.
Values below the LLOD were assigned half the LLOD
and values above the upper limit of detection (ULOD)
were assigned the ULOD.
Statistical analysis
Data sets used for analysis from COPDGene included:
the COPDGene Phase 2 5000 data set from September
24, 2016. Data sets used for analysis from SPIROMICS
included: the Core 4 datasets. R (v 3.2.0) was used for
analysis unless otherwise indicated. Differences in demo-
graphic characteristics of study subjects were assessed
using a t test or Chi squared test. Because of non-
normality, biomarker values were log10 transformed
(Additional file 1: Figure S1) and all statistical analysis
was done with the log10 value of the biomarker. Statis-
tical models and covariates were selected based on previ-
ous literature [9, 10, 14, 16, 25, 35, 36] as indicated in
Additional file 1: Table S2. Akaike Information Criteria
(AIC) was used to determine how well a model fit. The
R2 (adj) reported refers to the percent variation of the
phenotype explained by the biomarkers(s) over clinical
covariates alone. The adjusted R2 (adj) was used for esti-
mating the percent variation of FEV1% explained by the
biomarkers over clinical covariates alone using the Core
R package. For FEV1/FVC we reported the McFadden
pseudo-R2 [37] using the betareg package. For chronic
bronchitis we report the Cragg-Uhler pseudo R2 [38]
using the pscl package. For decline in FEV1 and emphy-
sema progression we report the marginal R2 [39] using
the MuMin package. Biomarker(s) were considered to
improve the model if the AIC was lower than clinical co-
variates alone and the p-value for the complete model
was less than 0.05. P-values were combined using Stouf-
fer’s Z-score method. Single nucleotide polymorphism
(SNP)-biomarker associations were assessed in non-
Hispanic White subjects with PLINK using genetic an-
cestry principal components, sex, age, body mass index
(BMI), smoking pack years and current smoker status as
previously described [34]. A cutoff of P < 10−9 was used
to account for multiple biomarker testing. For subgroup
analysis (Additional files 2 and 3), we calculated the P
values for the individual cytokine associations in the
same models that included the covariates described
above. Significant P-values (P < 0.05) for the cytokine ß
estimate in each clinical phenotype regression were
shaded on a heatmap according to the -1og10 scale of
the P – value. Colors were blue for negative associations,
red for positive associations, and grey for insufficient
endpoints.
Results
Demographics characteristics of subjects and associations
with biomarkers
Baseline characteristics of the COPDGene and SPIRO-
MICS subjects are shown in Table 1. The COPDGene
subjects included in this study were generally similar to
the SPIROMICS subjects, but the SPIROMICS subjects
were slightly younger, had lower BMI, greater smoking
intensity, and included a lower percentage of subjects
with moderate COPD and a higher percentage of sub-
jects with severe COPD. Most of the cytokines and che-
mokines were strongly associated with smoking status
and also showed association with age, race, BMI, and
gender (Additional file 1: Tables S3–S6). For instance,
current smoking was associated with lower IL-2 in both
cohorts, but higher CCL17 (TARC). Because of these as-
sociations, these covariates were included in statistical
models. Cytokines were also associated with multiple
different complete blood cell counts consistently be-
tween cohorts (Additional file 1: Figure S2).
Biomarkers associated with COPD affection status and
airflow obstruction
Four biomarkers (eotaxin, IL-6, IL-8, and IL-10) were
independently associated (P < 0.05) with worse airflow
obstruction (FEV1%) in both cohorts, even after adjust-
ment for clinical covariates (Table 2). Similar associations
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were seen for FEV1/FVC (Additional file 1: Table S7). Both
eotaxin and IL-6 were significantly higher in cases
compared to controls and were higher in severe
COPD compared to mild/moderate COPD (Fig. 1). In
a full regression model with clinical covariates,
plasma IL-6 accounted for an additional 4–5% of
variance of FEV1% and 2–3% variance of FEV1/FVC.
Other biomarkers accounted for less of the variance
in these and other outcomes (Additional file 1: Table S8).
Similar results were seen in subgroup analyses when
subjects were grouped on presence or absence of air-
flow obstruction (GOLD 1–4), chronic bronchitis, and
emphysema (Additional file 2); however, dividing the
cohort into 4 or more subgroups substantially re-
duced the power of the analyses. When adding bio-
markers to a model that included clinical covariates,
higher IL-6 was also associated with more rapid pro-
gression of airflow obstruction at 5 years in the
COPDGene cohort, but not over a 1 year follow up
in SPIROMICS (Additional file 1: Table S9). When
stratifying the COPDGene subjects by GOLD groups,
higher IL-6 was still associated with more rapid decline,
but the association was no longer significant when clinical
covariates were included in the model (Additional file 1:
Table S10). In the COPDGene cohort, there was a signifi-
cant association with 5-year decline in FEV1 and IL-6 in
subjects who did not have COPD or emphysema and sig-
nificant association with 5-year decline in FEV1 and IL-8
in subjects who had chronic bronchitis, but no emphy-
sema (Additional file 3). The amount of additional
variance in progression of FEV1 decline explained by
a IL-6 in addition to clinical covariates was 3%.
Table 1 Demographics of subjects
Never smokers
N = 25
COPDGene
N = 2098
SPIROMICS
N = 1117
p-value (SPIROMICS vs COPDGene)
(current and former smokers)
Age (years) 57.5 (7) 65.8 (8.9) 62.7 (9) < 10−04
Gender Male 36.0% 50.9% 51.9% 0.6931
Race
White 100.0% 71.2% 74.9%
Black 0.0% 28.4% 20.8%
Other 0.0% 0.0% 4.3%
Current Smoker 0% 34.7% 40.5% 0.0009
BMI (kg/m2) 25.7 (4.2) 28.8 (6.3) 28.2 (5.4) 0.0028
ATS Smoking, pack-years 0 (0) 45.1 (24) 47.6 (24.7) 0.0054
FEV1 (% predicted) 105.5 (12) 76.1 (25.6) 76.1 (28.7) 0.9906
FEV1/FVC 0.8 (0) 0.7 (0.2) 0.6 (0.2) < 10
−04
BODE Index 0.2 (0.4) 1.3 (1.7) 1.5 (2) 0.0084
SGRQ 2.7 (3.5) 23.6 (21.1) 32 (21.2) < 10−04
Emphysema (% LAA < −950 HU) 1 (1.3) 6.5 (10.2) 7.3 (10.4) 0.0386
Chronic Bronchitis (%) 4% 15.2% 20.9% < 10−04
Duration of participation in study (years) NA 6.7 (1.2) 2.2 (0.9) < 10−04
Decline in FEV1 (ml/year) NA −38.1 (53.4) −48.5 (144.1) 0.0416
Exacerbations (#/year) 0 (0) 0.3 (0.8) 0.5 (1.0) < 10−04
Never Smoker 100% 0% 0%
Spirometry category
PRISm 0% 10.4% 0%
Control Smoker 0% 41.5% 49.3%
GOLD 1 0% 9.3% 7.9%
GOLD 2 0% 20.4% 17.5%
GOLD 3 0% 12.2% 18.1%
GOLD 4 0% 5.8% 7.1%
Abbreviations: SGRQ St. George’s Respiratory Questionnaire, HU Hounsfield Unites, BODE Body-mass index, airflow Obstruction, Dyspnea, and Exercise, PRISm
preserved ratio, impaired spirometry, GOLD Global Initiative for Chronic Obstructive Lung Disease
P-values are not applicable to race, ever smoking, and spirometry category because these criteria were used as inclusion criteria in one or both studies
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Biomarkers associated with emphysema severity and
progression, chronic bronchitis and COPD exacerbations
Although none of the 9 biomarkers had independent
cross sectional associations with emphysema severity at
a single time point (LAA% < −950 HU), higher IL-6 and
IL-8 were associated with progression of CT assessed
emphysema over 5 years (Table 3). The IL-6 association
with emphysema progression was also seen in subgroup
analysis which included only subjects without COPD or
chronic bronchitis and no emphysema at baseline
(Additional file 3).
Biomarkers associated with emphysema severity and
progression, chronic bronchitis and COPD exacerbations
None of the 9 biomarkers were reproducibly associated
with chronic bronchitis. Although there were other
chemokines and cytokines that were associated with ex-
acerbations in either COPDGene or SPIROMICS
(Fig. 2), none of these associations were significant in
both cohorts.
Relationship between genotype and biomarker level
Because we recently reported that genetic factors can
also influence many different biomarker measurements
[34], we assessed associations between genetic variants
and biomarker measurements using protein quantitative
trait locus (pQTL) analysis (Additional file 1: Figure S3).
The rs9302690 SNP in CCL17 was the only genetic locus
Table 2 Biomarkers associated with FEV1%
COPDGene SPIROMICS Combined
Biomarker ß R2(adj) P ß R
2
(adj) P P
Eotaxin −12.2 0.007 0.0001 −31.3 0.039 < 10−10 < 10−12
CCL26 −1.7 0.000 0.2225 −3.4 0.001 0.1095 0.0679
CCL17 0.1 0.000 0.9383 −3.7 0.001 0.1664 0.3525
IFN-γ −6.2 0.006 0.0003 −4.5 0.002 0.0881 0.0002
IL10 −4.1 0.003 0.0072 −6.2 0.003 0.0442 0.0013
IL2 −2.8 0.002 0.0426 −7.2 0.007 0.0043 0.0016
IL6 −16.2 0.049 < 10−23 −21.1 0.042 < 10−11 < 10−34
IL8 −4.2 0.002 0.0226 −9.9 0.005 0.0091 0.0008
TNF-α −7.0 0.006 0.0004 −6.4 0.001 0.1725 0.0003
R2(adj) is the partial amount of variance explained by the biomarker in models
with clinical covariates
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Fig. 1 Plasma eotaxin and IL-6 are higher in subjects with COPD. Never smokers (never) and current and former smokers with no COPD (control),
mild/moderate COPD (Mild/Moderate), or severe or very severe COPD (Severe)
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significantly associated with a biomarker measurement
in both cohorts (P < 10−11 in COPDGene and P < 10−10
in SPIROMICS). The minor allele was (A) was asso-
ciated with higher levels of CCL17 (Additional file 1:
Figure S4) and occurs in intron 3 of CCL17. This is the
first report of this SNP being association with CCL17.
Discussion
Although tobacco smoke is inhaled though the lung,
there is substantial evidence that tobacco exposure has
systemic manifestations and is associated with extra-
pulmonary disease [2–5]. While the mechanisms of to-
bacco smoke-induced systemic injury are not fully
understood, inflammation is thought to play a key role.
This study is one of largest multiplex investigations of
cytokines and chemokine biomarkers to date and is one
of the few that includes two large, independent, well
phenotyped cohorts of current and former smokers. Al-
though we found that most of the cytokines and chemo-
kines were associated with some COPD phenotypes,
only eotaxin and IL-6 were strongly and consistently as-
sociated with airflow flow limitation in both cohorts,
even after adjustment for important clinical covariates.
None of the nine biomarkers were associated with
chronic bronchitis. None of the 9 biomarkers were con-
sistently associated with COPD exacerbations, which is
similar to what has been recently reported for COPD ex-
acerbations in a more extensive study of other blood
biomarkers, albeit with few subjects [40].
Eotaxin-1 (CCL11) is a potent eosinophil chemo-
attractant that is normally associated with asthma [41],
but is known to play a role in other mucosal diseases
such as inflammatory bowel disease (see review [42]).
Eotaxin and eotaxin receptor (CCR3) positive cells are
higher in acute exacerbations of chronic bronchitis as
well as asthma [43]; however, the published associations
between plasma eotaxin and COPD in non-exacerbating
subjects are contradictory, possibly because most include
only a small number of subjects. For instance, in 50
FORTE study participants (34 stable and 16 rapid de-
cliners) and 11 controls, plasma eotaxin-1 was lower in
Table 3 biomarkers associated with progression of emphysema
COPDGene
Biomarker Value s.e. P
Eotaxin 0.177 0.102 0.0835
CCL26 −0.011 0.046 0.8060
CCL17 0.010 0.048 0.8390
IFN-γ −0.039 0.056 0.4865
IL10 0.081 0.050 0.1093
IL2 −0.033 0.047 0.4857
IL6 0.153 0.054 0.0042
IL8 0.145 0.062 0.0196
TNF-α 0.088 0.066 0.1832
 
FEV1/FVC 
FEV1% 
Emphysema Severity 
Chronic Bronchitis 
Mod/Sev. Exacerbations 
Severe Exacerbations 
Fig. 2 Heat map showing associations between cytokines and chemokines and COPD clinical phenotypes in the COPDGene and SPIROMICS
cohorts. The intensity of the color represents the log of the P-value with red indicating positive associations and blue indicating negative associations
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rapid decliners compared to stable COPD patients, but
eotaxin was also significantly lower in stable COPD sub-
jects compared to normal controls (p < 0.03) [44]. In a
different study of 21 COPD subjects and 9 controls,
eotaxin was higher in COPD patients compared to con-
trols [45]. In our study, which included more than 3000
subjects, eotaxin was higher in COPD subjects in both
cohorts compared to control subjects with no COPD
and a comparable smoking history. Eotaxin was higher
in subjects with chronic bronchitis and was positively as-
sociated with neutrophils and negatively associated with
eosinophil counts. These findings suggest that eotaxin is
associated with a neutrophilic/inflammatory COPD, but
does not appear to be independently associated exacer-
bations or higher eosinophils, as might be expected with
asthma exacerbations.
Another strong association was between IL-6 and
COPD affection status, airflow limitation and emphy-
sema progression. IL-6 is a 26 kDa, 184 amino acid
multifunctional glycoprotein and pro-inflammatory cyto-
kine that is produced in a variety of stromal and im-
mune cells and which is associated with a large number
of pulmonary and extra-pulmonary inflammatory dis-
eases (see reviews [46, 47]). In this study, which is appre-
ciably larger than previously published studies, we found
that IL-6 was associated with both case-control status,
COPD severity, rate of decline in spirometry, and inde-
pendently associated with emphysema progression as
assessed by CT scans; however, it was not independently
associated with exacerbations. The case-control associa-
tions are consistent with several large population studies.
For example, in the Health, Aging, and Body Com-
position study which included 3075 subjects [48], the
Framingham Heart Study which included 2553 subjects
[49], the Rotterdam Study which included 572 older sub-
jects [50], plasma IL-6 was higher in those with COPD
compared to those without. This is consistent with a re-
cent meta-analysis of IL-6 and COPD, which included
1891 COPD subjects and 4946 controls from 33 studies
[51]. This meta-analysis also reported a non-statistically
significant trend toward the mild-moderate COPD sub-
jects having lower plasma IL-6 compared to severe
COPD subjects; however, IL-6 was not associated with
disease severity in 1793 subjects from in the ECLIPSE,
which primarily included COPD subjects [14]. IL-6 was
also not associated with decline in the ECLIPSE cohort.
Since IL-6 was strongly associated with neutrophils in
both cohorts, this would suggest that IL-6 may drive the
inflammatory phenotype which promotes progressive
airflow limitation. While our analysis showed a statisti-
cally significant independent association with decline in
lung function, adding IL-6 to the model with clinical co-
variates (e.g. low FEV1%) added only about 4–5% to the
explanation of variance. This is consistent with the
concept that subjects with low lung function have an in-
flammatory phenotype and are predisposed to more
rapid decline in lung function, and that adding bio-
markers to these prediction models will add a small, but
additional benefit to predicting decline on top of clinical
covariates.
The COPDGene study is one of the largest current
and former smoker cohorts with long term CT follow up
and this study is one of the first to report IL-6 as an in-
dependent biomarker of emphysema progression. A
pathologic role for IL-6 is supported by several observa-
tions. First, IL-6 binds to IL-6 receptor and signals
through at gp130 subunit; it transduces inflammatory
gene transcription through JAK-STAT pathways. Second,
genetic blockade of the IL-6 receptor subunit gp130
blocks cigarette smoke induced emphysema [52]. Third,
IL-6 is associated with cardiovascular disease in COPD
patients [53] and recent literature supports a vascular
etiology of emphysema [54]. Although IL-6 specific
treatments (e.g. tocilizumab) have been developed, but
not yet tried as a treatment for COPD, one case report
describes worsening of emphysema during treatment for
rheumatoid arthritis [55]. Thus, anti-IL-6 treatment in
COPD should be done with caution.
In additional to eotaxin and IL-6, IL-2, IL-8, and IL-10
were also found to be elevated in COPD patients, al-
though they accounted for only a small amount of the
variance in airflow obstruction compared to IL-6 and
eotaxin. For several of these cytokines, there are only
smaller studies previously published. In a study of 10
COPD patients and 10 controls, ex vivo IL-2 release
from stimulated T-cells was higher in COPD patients
compared to smoking controls [56]. In the 50 FORTE
study participants discussed above, IL-2 was higher in
COPD patients, but was lower in rapid decliners com-
pared to stable COPD patients [44]. Similarly, in small
studies IL-8 has been reported to be elevated in COPD
patients in smaller studies with less than 100 subjects
[57, 58]. This is the first large study to show that IL-8 is
independently associated with progression of emphy-
sema by CT scan and additional studies in independent
longitudinal COPD cohorts should consider measuring
IL-8. Similarly, we find that IL-10 is associated with
worse COPD; however, there are only a few published
studies, which may be underpowered to confirm or re-
fute these observations. For example in a study of 94
COPD patients and 45 controls, IL-10 was no different
between COPD patients and controls, but lower than in
healthy non-smokers [59]. Since IL-10 was not associ-
ated with progression of COPD or emphysema, it is un-
clear whether it may be a useful predictive marker.
Although CCL17 is more expressed in airway cells
from COPD patients and plays a role in Th2 inflamma-
tion [60], we found no association with any COPD
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phenotypes. However, our study is the first report of the
rs9302690 SNP being a pQTL for CCL17, with the
minor allele being associated with higher plasma levels
of CCL17. This finding may be relevant to other clinical
investigators because CCL17 is expressed in many tis-
sues and has been associated with atopic dermatitis [61]
and Hodgkin’s Lymphoma [62]. In GTex analysis, the
rs9302690 SNP is also a gene expression QTL (eQTL)
(GTEx V6p) with the minor allele being associated with
higher CCL mRNA in esophagus and testes and lower
expression in adrenal and pituitary tissue. Thus, both
CCL17 gene and protein expression should be adjusted
for the rs9302690 genotype.
While this study was unique in that it featured two
large well-characterized cohorts, confirmed strong asso-
ciations of IL-6 and eotaxin, identified new pQTL SNPs,
and identified potentially new biomarkers of COPD and
emphysema progression, there were some important
limitations. Most importantly, biomarkers were assessed
at only a single time point and thus one cannot deter-
mine whether the biomarkers temporally fluctuate with
disease activity. We also only studied 9 biologically
plausible biomarkers, but there are new platforms which
will permit the simultaneous measurements of hundreds
or thousands of proteins, even if these platforms may
not be designed to assay low abundant proteins such as
interleukins. Also, although subgrouping into pheno-
types showed that some cytokines such as IL-6 were as-
sociated with severity and progression of airflow
obstruction and emphysema even in subjects without
COPD or emphysema at baseline, other subgroup ana-
lyses were limited by the loss of power that occurred
when subgroup sizes dropped below 500 subjects. This
might suggest that biomarkers might be useful markers
of disease progression in current and former smokers
who do not yet manifest COPD or emphysema. Finally,
other limitations of this study include the relatively low
number of nonsmokers and only limited progression
data in one of the cohorts (SPIROMICS).
Conclusion
In summary, we show that selected cytokines such as
eotaxin and IL-6 explain a moderate amount of the clin-
ical COPD phenotypic variance (3–5%) when added to
models with clinical covariates. Eotaxin, IL-6, and IL-8
may also have some value independent of clinical vari-
ables in predicting progression, although this should be
demonstrated in other long term longitudinal cohorts
besides COPDGene. We remain optimistic that some of
these biomarkers may be useful for clinical trials, in which
biomarkers might define inclusion criteria in order to limit
trials to a subgroup of patients, e.g., those more likely to
progress and therefore more likely to benefit from a given
intervention. This has the potential to lead to the
identification of a therapies from which a specific group of
patients may benefit. In addition, biomarker combinations
may serve as surrogate endpoints if they are prospectively
demonstrated to correlate with clinically relevant out-
comes. For these reasons, consideration should be given
to development of panels of multiple biomarkers for
COPD observational and interventional studies.
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automated complete blood cell counts. The shading of each cell represents
the correlation coefficient as indicated in the legend. Figure S4. Combined
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genome wide significance level adjusted for multiple testing (P < 10−9).
Results for all 9 biomarkers are superimposed on the graph. Only one SNP
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